Silibinin mitigates AKI-to-CKD transition via MAPK and PI3K/AKT signaling pathways in Ischemia-Reperfusion injury
7.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-19 04:00
摘要：
Silibinin, a flavonolignan from Silybum marianum, has shown promise in mitigating the transition from acute kidney injury (AKI) to chronic kidney disease (CKD) by modulating MAPK and PI3K/AKT signaling pathways. This study highlights its potential as a therapeutic agent, addressing a significant global health challenge associated with high morbidity and mortality rates. The findings suggest that silibinin could improve long-term renal outcomes in patients at risk of CKD.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+重点关注领域符合度
business_impact
0.5分+商业影响力
scientific_rigor
1.5分+数据支撑的科学性
timeliness_innovation
1.5分+时效性与创新性
investment_perspective
2.5分+BOCG投资视角
market_value_relevance
1.0分+市场价值相关性
team_institution_background
0.5分+团队与机构背景
technical_barrier_competition
0.5分+技术壁垒与竞争格局
关键证据
Silibinin significantly decreased serum creatinine and blood urea nitrogen.
The study is the first to investigate silibinin's effects on AKI-to-CKD transition.
Silibinin modulated MAPK and PI3K/AKT signaling pathways.
真实性检查
否
AI评分总结
Silibinin, a flavonolignan from Silybum marianum, has shown promise in mitigating the transition from acute kidney injury (AKI) to chronic kidney disease (CKD) by modulating MAPK and PI3K/AKT signaling pathways. This study highlights its potential as a therapeutic agent, addressing a significant global health challenge associated with high morbidity and mortality rates. The findings suggest that silibinin could improve long-term renal outcomes in patients at risk of CKD.